ClinicalTrials.gg
CompletedNCT01928771Updated May 3, 2017Results posted

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 281 sites in 17 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-03.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,681
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
Largest of 39
2,681 · median 128
Started
2013
with 2 others
Phase 3
20 of 39
1 open now
Registered
8th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one has the largest enrollment, is one of 3 that started in 2013, is one of 20 in phase 3, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.

03

Conditions studied

  • Asthma

Keywords

  • Asthma,
  • Bronchial Diseases,
  • Respiratory Tract Diseases,
  • Lung Diseases,
  • Obstructive Lung Diseases
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable European Union guidelines.
  2. Female and Male aged 12 to 75 years inclusively, at the time of visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.
  3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250μg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1
  4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral and additional asthma controllers.

    • For subjects 18 years of age and older, the ICS dose must be >500 mcg/day fluticasone propionate dry powder formulation or equivalent daily.
    • For subjects ages 12-17, the ICS dose must be ≥500 mcg /day fluticasone propionate dry powder formulation or equivalent daily.

Exclusion criteria

Exclusion criteria:

  1. pulmonary disease other than asthma (e.g. active lung infection, , bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date is obtained or during the screening/run-in period
  4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2,681 participants (actual)

Study arms

  • Experimental
    Benralizumab 30 mg q.4 weeks

    Benralizumab administered subcutaneously every 4 weeks

    Biological: Benralizumab

  • Experimental
    Benralizumab 30 mg q.8 weeks

    Benralizumab administered subcutaneously every 8 weeks

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab subcutaneously on study week 0 until study week 44 inclusive.

  • BiologicalPlacebo

    Placebo subcutaneously on study week 0 until study week 44 inclusive.

06

What researchers measure

Primary outcomes

  1. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL

    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF

    Time frame: Immediately following the first administration of study drug through Study Week 48.

Secondary outcomes

  1. Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL

    The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  2. Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations

    The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  3. Number of Patients With >=1 Asthma Exacerbations

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  4. Time to First Asthma Exacerbation

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  5. Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  6. Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  7. Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL

    Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  8. Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL

    Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  9. Change in Asthma Rescue Medication

    Change from baseline to week 48 in number of rescue medication use (puffs/day)

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  10. Home Lung Function Assessment Based on Morning PEF

    Change from baseline to week 48 in home lung function morning peak expiratory flow \[PEF\]

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  11. Home Lung Function Assessment Based on Evening PEF

    Change from baseline to week 48 in home lung function evening peak expiratory flow \[PEF\]

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  12. Proportion of Night Awakening Due to Asthma

    Change from baseline to Week 48 on proportion of night awakening due to asthma

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  13. Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL

    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  14. Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL

    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  15. Pharmacokinetics of Benralizumab

    Mean PK concentrations at each visit

    Time frame: Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56

  16. Immunogenicity of Benralizumab

    Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

    Time frame: Pre-treatment until end of follow-up

  17. Extend of Exposure

    Extend of exposure is defined as duration of treatment in days

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  18. Mean Change From Baseline to Week 48 in AQLQ(S)+12

    AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  19. Mean Change From Baseline to Week 48 in EQ-5D-5L VAS

    EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  20. Mean Work Productivity Loss Due to Asthma

    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  21. Mean Productivity Loss Due to Asthma in Classroom

    WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  22. Number of Participants That Utilized Health Care Resources

    Time frame: Immediately following the first administration of study drug through Study Week 48.

  23. Patient and Clinician's Responder Assessment to Treatment

    CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.

    Time frame: Immediately following the first administration of study drug through Study Week 48

07

Results

Posted May 3, 2017

Participant flow

Participant flow — Overall Study
MilestoneBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Started400398407
Received treatment399398407
Completed354358367
Not completed464040
Withdrew: Adverse event651
Withdrew: Death222
Withdrew: Lost to follow-up563
Withdrew: Withdrawal by subject201517
Withdrew: Study-specific withdrawal criteria011
Withdrew: Other reasons9914
Withdrew: Severe non-compliance to protocol422

Outcome measures

PrimaryAnnual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL

The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Least squares mean · events/year
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL
events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL0.73 (0.60 to 0.89)0.65 (0.53 to 0.80)1.33 (1.12 to 1.58)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Negative binomial · p = <0.001 · Rate ratio: 0.55 · 95% CI 0.42 to 0.71Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Negative binomial · p = <0.001 · Rate ratio: 0.49 · 95% CI 0.37 to 0.64Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids
SecondaryAnnual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL

The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Least squares mean · events/year
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL
events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL0.85 (0.65 to 1.11)1.00 (0.78 to 1.28)1.21 (0.96 to 1.52)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Negative binomial · p = 0.047 · Rate ratio: 0.7 · 95% CI 0.5 to 1.0Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Negative binomial · p = 0.268 · Rate ratio: 0.83 · 95% CI 0.59 to 1.16Model includes covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids
SecondaryAnnual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations

The annual exacerbation rate associated with an emergency room visit or a hospitalization (adjudicated)

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Least squares mean · events/year
Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations
events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations0.11 (0.07 to 0.16)0.06 (0.04 to 0.11)0.18 (0.13 to 0.25)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Negative binomial · p = 0.053 · Rate ratio: 0.61 · 95% CI 0.37 to 1.01Model includes covariates treatment group, region, number of exacerbations resulting in ER/hospitalization in the previous year, and use of OCS
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Negative binomial · p = <0.001 · Rate ratio: 0.37 · 95% CI 0.2 to 0.67Model includes covariates treatment group, region, number of exacerbations resulting in ER/hospitalization in the previous year, and use of OCS
SecondaryNumber of Patients With >=1 Asthma Exacerbations
Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Number · Participants
Number of Patients With >=1 Asthma Exacerbations
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Number of Patients With >=1 Asthma Exacerbations100 ± 84.22793 ± 72.002135 ± 74.434
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 0.54 · 95% CI 0.37 to 0.78Controlling for region, number of exacerbations in the previous year, use of OCS
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = 0.01 · Odds ratio (or): 0.62 · 95% CI 0.43 to 0.90Controlling for region, number of exacerbations from the previous year, use of OCS
SecondaryTime to First Asthma Exacerbation
Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Median · Days
Time to First Asthma Exacerbation
DaysBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Time to First Asthma ExacerbationNA ± 84.227NA ± 72.002300 ± 74.434
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.63 · 95% CI 0.49 to 0.82Model includes treatment, number of exacerbations in the previous year, region, use of OCS
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.60 · 95% CI 0.46 to 0.78Model includes treatment, number of exacerbations from the previous year, region, use of OCS
SecondaryMean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL
Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Liter
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL0.353 ± 0.5030.398 ± 0.5460.237 ± 0.508
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.022 · Mean difference (final values): 0.106 · 95% CI 0.016 to 0.196Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 0.159 · 95% CI 0.068 to 0.249Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit
SecondaryMean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL
Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Liter
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL0.115 ± 0.4170.238 ± 0.4830.140 ± 0.4
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.644 · Mean difference (final values): -0.025 · 95% CI -0.134 to 0.083Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.057 · Mean difference (final values): 0.102 · 95% CI -0.003 to 0.208Model includes treatment, baseline pre-BD FEV1, region, use of OCS, visit and treatment by visit
SecondaryMean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL

Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL-1.15 ± 1.31-1.34 ± 1.27-1.03 ± 1.07
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.442 · Mean difference (final values): -0.08 · 95% CI -0.27 to 0.12Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.012 · Mean difference (final values): -0.25 · 95% CI -0.45 to -0.06Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment
SecondaryMean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL

Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL-0.98 ± 1.19-1.04 ± 1.24-0.78 ± 0.99
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.169 · Mean difference (final values): -0.2 · 95% CI -0.48 to 0.08Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.043 · Mean difference (final values): -0.29 · 95% CI -0.57 to -0.01Model includes treatment, baseline asthma symptom score, region, use of OCS, visit and visit by treatment
SecondaryChange in Asthma Rescue Medication

Change from baseline to week 48 in number of rescue medication use (puffs/day)

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Puffs/day
Change in Asthma Rescue Medication
Puffs/dayBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change in Asthma Rescue Medication-2.74 ± 4.29-2.78 ± 3.90-2.18 ± 4.38
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.1 · Mean difference (final values): -0.53 · 95% CI -1.16 to 0.10Model includes treatment, baseline asthma medication use, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.081 · Mean difference (final values): -0.57 · 95% CI -1.21 to 0.07Model includes treatment, baseline asthma medication use, region, use of OCS, visit and visit by treatment
SecondaryHome Lung Function Assessment Based on Morning PEF

Change from baseline to week 48 in home lung function morning peak expiratory flow \[PEF\]

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · L/min
Home Lung Function Assessment Based on Morning PEF
L/minBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Home Lung Function Assessment Based on Morning PEF45.857 ± 84.22736.994 ± 72.00222.059 ± 74.434
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 23.32 · 95% CI 9.20 to 37.43Model includes treatment, baseline morning PEF, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.025 · Mean difference (final values): 16.46 · 95% CI 2.08 to 30.83Model includes treatment, baseline morning PEF, region, use of OCS, visit and visit by treatment
SecondaryHome Lung Function Assessment Based on Evening PEF

Change from baseline to week 48 in home lung function evening peak expiratory flow \[PEF\]

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · L/min
Home Lung Function Assessment Based on Evening PEF
L/minBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Home Lung Function Assessment Based on Evening PEF36.806 ± 86.27133.460 ± 74.01714.784 ± 68.799
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 21.75 · 95% CI 7.86 to 35.65Model includes treatment, baseline evening PEF, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.008 · Mean difference (final values): 19.18 · 95% CI 5.09 to 33.28Model includes treatment, baseline evening PEF, region, use of OCS, visit and visit by treatment
SecondaryProportion of Night Awakening Due to Asthma

Change from baseline to Week 48 on proportion of night awakening due to asthma

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Proportion of nights
Proportion of Night Awakening Due to Asthma
Proportion of nightsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Proportion of Night Awakening Due to Asthma-0.314 ± 0.366-0.380 ± 0.385-0.26 ± 0.344
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.964 · Mean difference (final values): 0.00 · 95% CI -0.05 to 0.04Model includes treatment, baseline proportion of nights with nocturnal awakenings, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.012 · Mean difference (final values): -0.06 · 95% CI -0.11 to -0.01Model includes treatment, baseline proportion of nights with nocturnal awakenings, region, use of OCS, visit and visit by treatment
SecondaryMean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL

ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL-1.33 ± 1.18-1.47 ± 1.05-1.12 ± 1.15
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.111 · Mean difference (final values): -0.15 · 95% CI -0.34 to 0.04Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -0.29 · 95% CI -0.48 to -0.10Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment
SecondaryMean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL

ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL-0.77 ± 1.07-1.14 ± 1.11-0.89 ± 1.01
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.99 · Mean difference (final values): 0.00 · 95% CI -0.27 to 0.27Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.107 · Mean difference (final values): -0.22 · 95% CI -0.48 to 0.05Model includes treatment, baseline ACQ-6 score, region, use of OCS, visit and visit by treatment
SecondaryPharmacokinetics of Benralizumab

Mean PK concentrations at each visit

Time frame:
Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56
Reported as:
Geometric mean · ng/mL
Pharmacokinetics of Benralizumab
ng/mLBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Baseline (n=395, 386)NA ± NANA ± NA—
Week 4 (n=393, 375)632.84 ± 152.14629.89 ± 169.22—
Week 4 day 6 (n=54, 63)1368.98 ± 633.331273.7 ± 688.20—
Week 8 (n=377, 366)916.25 ± 142.53881.57 ± 156.12—
Week 16 (n=358, 350)1024.26 ± 174.08250.84 ± 228.25—
Week 24 (n=349, 344)926.62 ± 231.75184.08 ± 298.92—
Week 32 (n=260, 267)853.67 ± 248.6152.73 ± 394.18—
Week 40 (n=328, 333)967.15 ± 218.32157.22 ± 364.6—
Week 48 (n=333, 333)864.37 ± 283.87162.51 ± 352.46—
Week 56 (n=63, 67)51.7 ± 833.916.66 ± 321.88—
SecondaryImmunogenicity of Benralizumab

Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

Time frame:
Pre-treatment until end of follow-up
Reported as:
Number · Participants
Immunogenicity of Benralizumab
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Positive at any visit (n=402, 393, 407)475821
Base- and post baseline positive (n=393, 381, 396)2310
Only post baseline positive (n=396, 389, 402)394910
Persistently positive (n=396, 389, 402)233916
Transiently positive (n=396, 389, 402)18134
Only baseline positive (n=399, 385, 401)661
SecondaryExtend of Exposure

Extend of exposure is defined as duration of treatment in days

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Days
Extend of Exposure
DaysBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Extend of Exposure285.86 ± 67.446288.02 ± 66.683289.38 ± 61.527
SecondaryMean Change From Baseline to Week 48 in AQLQ(S)+12

AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 48 in AQLQ(S)+12
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in AQLQ(S)+121.44 ± 1.181.56 ± 1.171.25 ± 1.18
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.081 · Mean difference (final values): 0.18 · 95% CI -0.02 to 0.37Model includes covariates treatment, baseline AQLQ(S)+12 score, region, use of OCS, visit, and visit by treatment
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.004 · Mean difference (final values): 0.3 · 95% CI 0.1 to 0.5Model includes covariates treatment, baseline AQLQ(S)+12 score, region, use of OCS, visit, and visit by treatment
SecondaryMean Change From Baseline to Week 48 in EQ-5D-5L VAS

EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Scores on a scale
Mean Change From Baseline to Week 48 in EQ-5D-5L VAS
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Change From Baseline to Week 48 in EQ-5D-5L VAS13.5 ± 21.8216.5 ± 23.6612.5 ± 21.41
SecondaryMean Work Productivity Loss Due to Asthma

WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. The work productivity loss is only applicable to patients who employed, which is only subset of the study population.

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Percent of productivity loss
Mean Work Productivity Loss Due to Asthma
Percent of productivity lossBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Work Productivity Loss Due to Asthma23.31 ± 24.16926.11 ± 23.0635.36 ± 24.537
SecondaryMean Productivity Loss Due to Asthma in Classroom

WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable to patients who attending classes

Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Mean · Percent of productivity loss
Mean Productivity Loss Due to Asthma in Classroom
Percent of productivity lossBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Mean Productivity Loss Due to Asthma in Classroom30.97 ± 25.31127.17 ± 38.45649.1 ± 25.801
SecondaryNumber of Participants That Utilized Health Care Resources
Time frame:
Immediately following the first administration of study drug through Study Week 48.
Reported as:
Number · Participants
Number of Participants That Utilized Health Care Resources
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Hospitalizations141220
Emergency department visits201026
Unscheduled outpatient visits7787109
Home visits213
Telephone calls464162
Ambulance transports639
SecondaryPatient and Clinician's Responder Assessment to Treatment

CGIC (Clinical global impression of change), and PGIC (Patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse). This is additional measures collected after second Amendment, thus not all patients had data to be analyzed.

Time frame:
Immediately following the first administration of study drug through Study Week 48
Reported as:
Number · Participants
Patient and Clinician's Responder Assessment to Treatment
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
CGIC improved807688
CGIC much improved595858
CGIC very much improved18125
CGIC total responder157146151
PGIC improved848091
PGIC much improved555865
PGIC very much improved261911
PGIC total responder165157167

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benralizumab 30 mg q.4 Weeks—51/403 (12.7%)214/403 (53.1%)
Benralizumab 30 mg q.8 Weeks—54/394 (13.7%)199/394 (50.5%)
Placebo—58/407 (14.3%)219/407 (53.8%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders23/40324/39432/407
PneumoniaInfections and infestations0/4032/3943/407
HypertensionVascular disorders0/4032/3940/407
Cholecystitis acuteHepatobiliary disorders2/4030/3941/407
InfluenzaInfections and infestations2/4030/3941/407
Nasal polypsRespiratory, thoracic and mediastinal disorders2/4030/3941/407
Urinary tract infection bacterialInfections and infestations0/4030/3942/407
OsteoarthritisMusculoskeletal and connective tissue disorders1/4030/3942/407
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/4030/3942/407
HypercoagulationBlood and lymphatic system disorders0/4031/3940/407
Most frequent other events
Showing 10 of 18
Most frequent other events
EventBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders48/40327/39460/407
NasopharyngitisInfections and infestations47/40347/39449/407
Upper respiratory tract infectionInfections and infestations45/40332/39437/407
HeadacheNervous system disorders31/40337/39421/407
BronchitisInfections and infestations27/40319/39430/407
SinusitisInfections and infestations18/40322/39429/407
PharyngitisInfections and infestations17/40323/39414/407
InfluenzaInfections and infestations15/40319/39423/407
ArthralgiaMusculoskeletal and connective tissue disorders11/40318/39412/407
PyrexiaGeneral disorders16/40312/3948/407

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlaceboTotal
Mean50.1 ± 13.447.6 ± 14.548.7 ± 14.948.8 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlaceboTotal
Female275252269796
Male124146138408
08

Study locations

281 sites
  • Research Site
    Foley, Alabama, United States
  • Research Site
    Huntsville, Alabama, United States
  • Research Site
    Mobile, Alabama, United States
  • Research Site
    Scottsboro, Alabama, United States
  • Research Site
    Sheffield, Alabama, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Bakersfield, California, United States
  • Research Site
    Beverly Hills, California, United States
  • Research Site
    Costa Mesa, California, United States
  • Research Site
    Huntington Beach, California, United States
  • Research Site
    Huntington Park, California, United States
  • Research Site
    Los Angles, California, United States
  • Research Site
    Newport Beach, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    Riverside, California, United States
  • Research Site
    San Jose, California, United States
  • Research Site
    Santa Ana, California, United States
  • Research Site
    Hartford, Connecticut, United States
  • Research Site
    New Haven, Connecticut, United States
  • Research Site
    Brandon, Florida, United States
  • Research Site
    Clearwater, Florida, United States
  • Research Site
    Cutler Bay, Florida, United States
  • Research Site
    DeLand, Florida, United States
  • Research Site
    Gainesville, Florida, United States
  • Research Site
    Hialeah, Florida, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Homestead, Florida, United States
  • Research Site
    Jackonsville, Florida, United States
  • Research Site
    Lynn Haven, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Pembroke Pines, Florida, United States
  • Research Site
    Port Charlotte, Florida, United States
  • Research Site
    Sebring, Florida, United States
  • Research Site
    St Petersburg, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Vero Beach, Florida, United States
  • Research Site
    Winter Park, Florida, United States
  • Research Site
    Albany, Georgia, United States
  • Research Site
    Gainesville, Georgia, United States
  • Research Site
    Lawrenceville, Georgia, United States
  • Research Site
    Gurnee, Illinois, United States
  • Research Site
    Normal, Illinois, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    Fort Mitchell, Kentucky, United States
  • Research Site
    Hazard, Kentucky, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Opelousas, Louisiana, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Gardner, Massachusetts, United States
  • Research Site
    North Dartmouth, Massachusetts, United States
  • Research Site
    Quincy, Massachusetts, United States
  • Research Site
    Farmington Hills, Michigan, United States
  • Research Site
    Rochester, Minnesota, United States
  • Research Site
    St. Paul, Minnesota, United States
  • Research Site
    Picayune, Mississippi, United States
  • Research Site
    Billings, Montana, United States
  • Research Site
    Bellevue, Nebraska, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Sparks, Nevada, United States
  • Research Site
    Marlton, New Jersey, United States
  • Research Site
    Northfield, New Jersey, United States
  • Research Site
    Union, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Bronx, New York, United States
  • Research Site
    Hopewell Jct, New York, United States
  • Research Site
    New York City, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Staten Island, New York, United States
  • Research Site
    Huntersville, North Carolina, United States
  • Research Site
    Shelby, North Carolina, United States
  • Research Site
    Winston-Salem, North Carolina, United States
  • Research Site
    Grand Forks, North Dakota, United States
  • Research Site
    Oregon, Ohio, United States
  • Research Site
    Toledo, Ohio, United States
  • Research Site
    Wooster, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Tulsa, Oklahoma, United States
  • Research Site
    Erie, Pennsylvania, United States
  • Research Site
    Feasterville, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Phoenixville, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Warwick, Rhode Island, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Easley, South Carolina, United States
  • Research Site
    Hodges, South Carolina, United States
  • Research Site
    Mt Pleasant, South Carolina, United States
  • Research Site
    Rock Hill, South Carolina, United States
  • Research Site
    Chattanooga, Tennessee, United States
  • Research Site
    Germantown, Tennessee, United States
  • Research Site
    Allen, Texas, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    Dickinson, Texas, United States
  • Research Site
    Duncanville, Texas, United States
  • Research Site
    Georgetown, Texas, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    McAllen, Texas, United States
  • Research Site
    McKinney, Texas, United States

Showing the first 100 of 281 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14. PubMed 35287231 ↗
  • Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Aug;125(2):171-176. doi: 10.1016/j.anai.2020.04.011. Epub 2020 Apr 22. PubMed 32334141 ↗
  • Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14. PubMed 31836949 ↗
  • Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15. PubMed 31626906 ↗
  • Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23. PubMed 30802500 ↗
  • Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct 18;52(4):1800936. doi: 10.1183/13993003.00936-2018. Print 2018 Oct. PubMed 30139780 ↗
  • DuBuske L, Newbold P, Wu Y, Trudo F. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018 Sep 4;39(5):345-349. doi: 10.2500/aap.2018.39.4162. Epub 2018 Aug 4. PubMed 30077185 ↗
  • Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018 May;120(5):504-511.e4. doi: 10.1016/j.anai.2018.01.030. Epub 2018 Feb 1. PubMed 29409951 ↗
  • Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5. PubMed 27609408 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2013
First posted
Aug 27, 2013
Start
Sep 19, 2013
Primary completionActual
Apr 5, 2016
CompletionActual
Apr 5, 2016
Results first posted
May 3, 2017
Last update
May 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01928771
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 27, 2013
Start date
Sep 19, 2013
Primary completion
Apr 5, 2016
Completion
Apr 5, 2016
Results posted
May 3, 2017
Last update
May 3, 2017

Study contacts

Eugene R. Bleecker, MD, Professor of Medicine
principal investigator · Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, North Carolina 27157

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion